Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81%
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Enlivex Therapeutics Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enlivex Therapeutics Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Cash Equivalents
$26.7m
CAGR 3-Years
100%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Cash Equivalents
$72m
CAGR 3-Years
-10%
CAGR 5-Years
21%
CAGR 10-Years
15%
Urogen Pharma Ltd
NASDAQ:URGN
Cash Equivalents
$124.9m
CAGR 3-Years
31%
CAGR 5-Years
14%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Cash Equivalents
â‚Ş14.1m
CAGR 3-Years
-44%
CAGR 5-Years
59%
CAGR 10-Years
40%
Pluri Inc
NASDAQ:PLUR
Cash Equivalents
$3.2m
CAGR 3-Years
-40%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

Back to Top